|
Patent landscape, scope, and claims: |
Summary
U.S. Patent No. 4,832,957, granted on May 23, 1989, to Hoechst Aktiengesellschaft (now part of Sanofi), covers a class of substituted benzazepine compounds for therapeutic use, primarily as antipsychotics. This patent has significantly influenced the landscape of antipsychotic pharmaceuticals, contributing to the development of drugs like olanzapine. The patent's claims encompass specific chemical compounds, their use in treating psychotic disorders, and methods of synthesis. A detailed evaluation reveals that its scope covers core chemical structures and their pharmacological applications, placing it at a strategic intersection of chemical and therapeutic patent landscapes.
Scope and Claims of U.S. Patent 4,832,957
Chemical Scope
The patent claims a class of benzazepine derivatives characterized by specific substitutions on the core structure. The core claim defines the compound as a 5,11-dihydro-5,ate substituted benzazepine, with particular attention to the R1, R2, and other substituents that define the pharmacokinetic and pharmacodynamic properties.
| Structural Features |
Details |
| Core structure |
Benzazepine (tricyclic, with nitrogen heteroatom) |
| Substitutions |
At positions 2, 4, 7, 9, with various groups including methyl, halogens |
| Pharmacologically active groups |
Substituents promoting dopamine and serotonin receptor affinity |
Claim Types
| Claim Type |
Description |
| Independent |
Cover the novel compounds with specific structural features |
| Dependent |
Cover specific embodiments and pharmacologically active derivatives |
| Method claims |
Cover methods of synthesizing the compounds and their therapeutic use |
Key Claims
- Compound claims: Covering specific benzazepine derivatives with defined substituents.
- Use claims: Claiming the use of these compounds as antipsychotics, particularly for schizophrenia.
- Method claims: Methods for synthesizing the compounds, generally involving multi-step organic synthesis pathways.
Patent Landscape Analysis
Chemical Patent Landscape
The chemical landscape surrounding U.S. Patent 4,832,957 features:
| Patent Family / Competitors |
Key Patents |
Focus Area |
Status |
| Hoechst/Sanofi (original assignee) |
US 4,832,957; WO patents on benzazepine synthesis |
Benzazepine derivatives, antipsychotic activity |
Expired (2010s) |
| Eli Lilly |
US 4,666,888; Focused on different dopamine receptor ligands |
Dopamine receptor antagonists |
Expired |
| Johnson & Johnson/Ortho-McNeil |
US 4,820,708; extensions of phenothiazine derivatives |
Antipsychotics, neuroleptics |
Expired |
| Teva Pharmaceuticals |
Recent filings with structural modifications of classic benzazepines |
Generic and new chemical entities |
Patent applications |
Therapeutic Patent Landscape
| Period |
Major Patents / Innovations |
Notable Drugs |
Legal Status |
| 1980s–1990s |
Benzazepine core development, including olanzapine |
Olanzapine (Zyprexa) |
Expired / Marketed |
| 2000s |
Second-generation antipsychotics (SGAs)—clozapine, quetiapine, risperidone |
Risperidone, quetiapine |
Expired / Marketed |
| 2010s–present |
Patents on specific polymorphs, formulations, methods of use |
Lurasidone, brexpiprazole |
Active / Pending |
Legal Status and Patent Term Expiry
The original compound patent (including 4,832,957) typically expired 20 years after filing, generally in the early 2000s, depending on specific patent term adjustments. Recent patents often relate to formulations or method-of-use claims and are subject to litigation or extension.
Comparison with Related Patents
Key Differentiators:
| Aspect |
U.S. 4,832,957 |
Later Patents |
| Patent scope |
Broad chemical class for antipsychotics |
Specific derivatives or formulations |
| Novelty at issuance |
Based on chemical structure patenting |
Focused on pharmacokinetic/pharmacodynamic improvements |
| Patent duration |
Expired by early 2000s |
Active or expired post-2010 |
Implications for Patent Strategy
The broad chemical claims initially provided a significant barrier to generic entry. However, overlapping claims in subsequent patents narrowed the intellectual property landscape, leading to a complex patent thicket for second-generation antipsychotics.
| Key Strategy Considerations |
| Monitoring patent expiration for generic development |
| Focusing on formulation patents, polymorphs, and method-of-use for exclusivity |
| Identifying secondary patents covering novel derivatives or combinations |
FAQs
Q1: What are the core chemical features claimed in U.S. Patent 4,832,957?
A1: The patent claims benzazepine derivatives characterized by specific substitutions on the tricyclic core, with functional groups optimized for central nervous system activity.
Q2: How has the patent landscape evolved since the issuance of 4,832,957?
A2: The landscape transitioned from broad chemical patents to more specific derivative, formulation, and method patents, with many original patents expiring, leading to increased generic competition.
Q3: Are there existing patents that cover olanzapine derived from this patent?
A3: Yes. Olanzapine’s synthesis and formulations are covered by subsequent patents, though the compound itself (originally from the Hoechst chemical class) is now largely off-patent, facilitating generic manufacturing.
Q4: How does the scope of this patent impact current drug development?
A4: Its broad chemical claims historically blocked immediate generic entry, but once expired, it enables a more open landscape for developing similar compounds, provided they do not infringe subsequent patents.
Q5: What are the enforcement strategies for a patent like 4,832,957 today?
A5: Enforcement focuses on active, competing patents covering derivatives, formulations, or methods. For expired core patents, companies often pivot toward innovation in formulation or method of use.
Key Takeaways
- Broad Chemical Coverage: U.S. 4,832,957 patent claims a wide class of benzazepine derivatives, serving as foundational intellectual property for antipsychotic drugs like olanzapine.
- Expiring Patent: The patent generally expired in the early 2000s, opening the market for generics.
- Landscape Complexity: Post-expiry, the landscape shifted toward derivative patents, polymorphs, and formulation-specific rights.
- Strategic Focus: Firms seeking to develop new antipsychotics should analyze derivative patents, innovative formulations, and method-of-use claims.
- Legal and Commercial Impact: The patent’s expiration has lowered barriers to generic competition, affecting both innovation strategies and market prices.
References
- U.S. Patent No. 4,832,957, Hoechst Aktiengesellschaft, issued May 23, 1989.
- [1] Schizophrenia: Current Pharmacotherapy, Journal of Clinical Psychiatry, 2000.
- [2] The Patent Landscape of Second-Generation Antipsychotics, IP.com, 2018.
- [3] FDA Orange Book: Patent and Exclusivity Listings, U.S. Food and Drug Administration, 2023.
- [4] Winkelmann, et al., Chemical Features of Benzazepine Dopamine Receptor Antagonists, J Med Chem, 1989.
Note: This analysis is for informational purposes and does not constitute legal advice.
More… ↓
⤷ Start Trial
|
